| Subject: | FDA Issues Public Health Advisory For Raptiva |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 19 Feb 2009 - 12:00 pm |
| The U.S. Food and Drug Administration (FDA) has issued a public health advisory concerning three confirmed and one possible report of progressive multifocal leukoencephalopathy (PML) in patients using the psoriasis drug Raptiva (efalizumab). Three of those patients have died. All four patients were treated with the drug for more than three years. None of the patients were receiving other treatments that suppress the immune system. The FDA is reviewing this latest information and states that it... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
